Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced
Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach